

DAFTAR PUSTAKA

1. Sari GK, Sarifuddin, Setyawati T. Tuberkulosis Paru Post Wodec Pleural Efusion: Laporan Kasus Pulmonary Tuberculosis Post Wodec Pleural Effusion: Case Report. J Med Prof [Internet] 2022;4(2):174–82. Available from: <https://jurnal.fk.untad.ac.id/index.php/medpro/article/download/761/420>[cited 2025 Feb 10]
2. WHO. Global Tuberculosis Report. 2023.
3. Kementerian Kesehatan RI. Laporan Program Penanggulangan Tuberkulosis Tahun 2022. 2022;
4. Perhimpunan Dokter Paru Indonesia. Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia. 2021.
5. Ramadhani Paduan Ratu A, Shalshabil M, Putri Amalia S. Resistensi Obat Anti Tuberkulosis Terhadap Pasien Tuberkulosis Paru Dengan Komorbid. 2024;1:156–67. Available from: <https://doi.org/10.572349/husada.v1i1.363>[cited 2025 Feb 22]
6. Dirjen P2P Kemenkes RI. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistensi Obat di Indonesia. 2020.
7. Imam FRS, Umboh JML, Tuda JSB. Faktor-faktor Risiko yang Berhubungan dengan Kejadian Multidrug-Resistant Tuberculosis (TB-MDR) di Kota Ternate, Maluku Utara. e-CliniC 2023;11(3):260–8.
8. Chen Y, Chen W, Cheng Z, Chen Y, Li M, Ma L, et al. Global burden of HIV-negative multidrug- and extensively drug-resistant tuberculosis based on Global Burden of Disease Study 2021. Sci One Heal 2024;3(July).
9. Kementerian Kesehatan RI. Laporan Program Penanggulangan Tuberkulosis. 2023;Available from: https://www.tbindonesia.or.id/wp-content/uploads/2024/12/Laporan-Program-Penanggulangan-TBC-2023_Final.pdf [cited 2025 Feb 22]
10. Mahu GFPH. Faktor-Faktor yang Mempengaruhi Pengobatan Pasien Tuberkulosis Resistensi Obat Di RSUP Dr. Sardjito Yogyakarta. 2022;1–128.
11. Kassa GM, Tadesse A, Gelaw YA, Alemayehu TT, Tsegaye AT, Tamirat KS, et al. Predictors of mortality among multidrug-resistant tuberculosis patients in central Ethiopia: a retrospective follow-up study. Epidemiol Infect 2020;148:e258.
12. Deviernur SM. Faktor-faktor yang mempengaruhi Kematian Pasien Tuberkulosis Resistensi Obat (TB RO) Selama Masa Pengobatan di Indonesia. 2023;
13. Getahun GK, Gezahegn E, Endazawaw G, Shitemaw T, Negash Z, Dessu S. Survival status and risk factors for mortality among multidrug-resistant tuberculosis patients in Addis Ababa, Ethiopia: A retrospective follow-up study. J Clin Tuberc Other Mycobact Dis 2023;33:100398.
14. Fantaw D, Feyissa M, Hamid S, Shibeshi W. Assessment of the survival status and risk factors for the mortality among multidrug resistant tuberculosis

- patients at Adama and Bishoftu general hospitals, Oromia, Ethiopia: a retrospective cohort study. *Adv Pharmacoepidemiol Drug Saf* 2018;7(1):1000222.
15. Massud A, Khan AH, Syed Sulaiman SA, Ahmad N, Shafqat M, Ming LC. Unsuccessful treatment outcome and associated risk factors. A prospective study of DR-TB patients from a high burden country, Pakistan. *PLoS One* 2023;18(8):e0287966.
 16. Van LH, Phu PT, Vinh DN, Son VT, Hanh NT, Nhat LTH, et al. Risk factors for poor treatment outcomes of 2266 multidrug-resistant tuberculosis cases in Ho Chi Minh City: a retrospective study. *BMC Infect Dis* 2020;20:1–10.
 17. Adamu AL, Aliyu MH, Galadanci NA, Musa BM, Lawan UM, Bashir U, et al. The impact of rural residence and HIV infection on poor tuberculosis treatment outcomes in a large urban hospital: a retrospective cohort analysis. *Int J Equity Health* 2018;17:1–11.
 18. Soeroto AY, Nurhayati RD, Purwiga A, Lestari BW, Pratiwi C, Santoso P, et al. Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia. *PLoS One* 2022;17(1):e0263304.
 19. Prihanti, Sari GS, Pratiwi NP, Mabruukah DA, Hutami LP, Sekarwangi D, et al. Analisis Faktor Yang Menghambat Penemuan Suspek Penderita Tuberkulosis di Puskesmas X. 2018;40–8.
 20. Kemenkes RI. Pedoman Nasional Pelayanan Kedokteran: Tatalaksana Tuberkulosis. Jakarta Kementerian Kesehatan Republik Indonesia 2020;
 21. Ardanari, R A. Tuberkulosis. Yog: DEEPUBLISH; 2018.
 22. Rahayu SR. Kualitas Pelayanan Kesehatan Tuberkulosis melalui Quote Tb Light sebagai Upaya “To End Tb.” *Inov Sains dan Kesehatan* 2021;3.
 23. Indrasari AD, Fathana PB. Studi Literatur: Patogenesis Dan Diagnosis Tuberkulosis Resisten Obat. *J Med Malahayati* 2024;8(1):162–9.
 24. Dean AS, Cox H, Zignol M. Epidemiology of drug-resistant tuberculosis. Strain Var Mycobacterium Tuberc complex its role *Biol Epidemiol Control* 2017;209–20.
 25. Husni V. Faktor-Faktor Yang Berhubungan Dengan Kejadian Tuberkulosis Paru Di Wilayah Kerja Puskesmas Tarok Kota Payakumbuh Provinsi Sumatera Barat. 2023;Available from: <https://repository.unja.ac.id/61242/>[cited 2025 Feb 22]
 26. Kemenkes RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tahun 2016 Tentang Penanggulangan Tuberkulosis. 2016;163.
 27. Rita E, Qibtiyah SM. Hubungan kontak penderita tuberkulosis terhadap kejadian tuberkulosis paru pada anak. *Indones J Nurs Sci Pract* 2020;3(1):35–41.
 28. Kusnanto P, Eko V, Pakiding H, Nurwidiastih D. Multidrug resistant tuberculosis (MDR-TB): tinjauan epidemiologi dan faktor risiko efek samping obat anti tuberkulosis. *Maj Kedokt Bandung* 2014;46(4):189–96.
 29. Long R, Divangahi M, Schwartzman K. Chapter 2: Transmission and

- pathogenesis of tuberculosis. *Can J Respir Crit Care, Sleep Med* 2022;6(sup1):22–32.
30. Jang JG, Chung JH. Diagnosis and treatment of multidrug-resistant tuberculosis. *Yeungnam Univ J Med* 2020;37(4):277–85.
 31. Kementerian Kesehatan Republik Indonesia. Surat Edaran Paduan Pengobatan TB-RO. Kementeri. Kesehat. Republik Indones.2020;
 32. Aviana F, Jati SP, Budiyan RT. Systematic Review Pelaksanaan Programmatic Management of Drug-Resistant Tuberculosis Pada Pasien Tuberkulosis Resistan Obat. *J Kesehat Masy* 2021;9(2):215–22.
 33. Noveyani AE, Martini S. Evaluasi Program Pengendalian Tuberkulosis Paru Dengan Strategi DOTS Di Puskesmas Tanah Kalikedinding Surabaya. *J Berk Epidemiol* 2014;2(2):251–62.
 34. Ige OM, Oladokun RE. Time to sputum culture conversion and treatment outcome among the first cohort of multidrug resistant tuberculosis patients in a high burden country. *Indian J Tuberc* 2018;65(4):322–8.
 35. World Health Organization. A conceptual framework for action on the social determinants of health. In: A conceptual framework for action on the social determinants of health. 2010.
 36. Pedersen OS, Holmgaard FB, Mikkelsen MKD, Lange C, Sotgiu G, Lillebaek T, et al. Global treatment outcomes of extensively drug-resistant tuberculosis in adults: A systematic review and meta-analysis. *J Infect* 2023;87(3):177–89.
 37. BPS Sumatera Barat. Sumatera Barat Dalam Angka 2024. Ber Resmi Badan Pus Stat 2024;54:1125.
 38. Badan Pusat Statistik. Peraturan Kepala Badan Pusat Statistik Nomor 120 Tahun 2020 Tentang Klasifikasi Desa Perkotaan Dan Perdesaan Di Indonesia 2020 Buku 1 Sumatera [Internet]. 2021. Available from: <https://disparbud.bandungkab.go.id/>
 39. Dinas Kesehatan Provinsi Sumatera Barat. Profil Kesehatan Provinsi Sumatera Barat 2023. 2023;
 40. DB ADSAP. Immunosenescence: emerging challenges for an ageing population. *Immunology* 2017;120(4):435–46.
 41. EL HKMPHRWRC. Sex differences in tuberculosis burden and notifications in low- and middle-income countries: a systematic review and meta-analysis. *PLoS Med* 2016;13(9):e1002119.
 42. Hirasen K, Berhanu R, Evans D, Rosen S, Sanne I, Long L. High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. *PLoS One* 2018;13(10):1–13.
 43. Anyamele OD, Nwokolo E AC. Geographic variations in TB mortality and health access disparities in Nigeria. *Afr J Respir Med* 2021;17(2):12–8.
 44. Ahmad N, Javaid A, Basit A et al. isk factors for poor outcomes among patients with extensively drug-resistant tuberculosis (XDR-TB): a retrospective cohort study. *BMC Infect Dis* 2017;17:371.
 45. al. EMLKCMFZKSTR et. Determinants of drug-resistant tuberculosis:

- analysis of 11 countries. *Int J Tuberc Lung Dis* 2021;5(10):887–93.
46. GA SDYSB. A systematic review of delay in the diagnosis and treatment of tuberculosis. *BMC Public Health* 2018;8:15.
 47. Wu Q, Liu X, Zhang Y et al. Risk factors for mortality among MDR-TB patients in China: a nationwide retrospective study. *BMJ Open* 2019;
 48. al. ANJABAAAKMAI et. Management and treatment outcomes of MDR-TB: results from a national program in Pakistan. *Int J Tuberc Lung Dis* 2015;19(4):478–84.
 49. Seung KJ, Omatayo DB, Keshavjee S et al. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in southern Africa. *Int J Tuberc Lung Dis* 2018;22(9):6.

